FDA Suspends Chikungunya Vaccine Over Safety Concerns
The U.S. Food and Drug Administration (FDA) announced on Aug. 22, 2025 that it has suspended the license for French drugmaker Valneva’s chikungunya vaccine, warning that its continued use “poses a danger to public health” following a risk–benefit analysis conducted by the agency’s Center for Biologics Evaluation and Research (CBER). The decision came after reports […]
FDA, CDC Halt Use of Chikungunya Vaccine in Adults 60+ After Two Deaths Reported
On May 9, 2025, the U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) recommended a temporary pause in the use of Ixchiq, a live virus vaccine designed to prevent chikungunya virus infection, in adults aged 60 years and older. The recommendation follows reports of serious post-marketing adverse […]
WHO Prequalifies Takeda’s Qdenga Dengue Vaccine
On May 10, 2024, the World Health Organization (WHO) granted prequalification status to the Qdenga (TAK-003) dengue vaccine, developed by Takeda Pharmaceutical Company Ltd. of Tokyo, Japan. The live attenuated virus vaccine is recommended to be given in two doses three months apart to children six to 16 years old living in areas where dengue […]